1. WHO. Dementia. 2022  [cited 2022 2022-11-22]; Available from: https://www.who.int/news-room/fact sheets/detail/dementia#:~:text=Rates%20of%20dementia,and%20139%20million%20in%202050.

2. Marucci, G., et al., Efficacy of acetylcholinesterase inhibitors in Alzheimer's disease. Neuropharmacology, 2021. 190: p. 108352.

3. Jones, R.W., Drug treatment for people with dementia. Clin. Med. (Lond), 2011. 11(1): p. 67-71.

4. Casey, D.A., D. Antimisiaris, and J. O’Brien, Drugs for Alzheimer’s disease: Are they effective? Pharm. Therapeut., 2010. 35(4): p. 208.

5. Colovic, M.B., et al., Acetylcholinesterase inhibitors: Pharmacology and toxicology. Curr. Neuropharmacol., 2013. 11(3): p. 315-335.

6. Ohbe, H., et al., Cholinergic crisis caused by cholinesterase inhibitors: A retrospective nationwide database study. J. Med. Toxicol., 2018. 14(3): p.

237-241.

7. Singh, R. and N.M. Sadiq, Cholinesterase inhibitors, in StatPearls. 2022, StatPearls Publishing: Treasure Island, FL.

8. Cavazzoni, P., The Path Forward: Advancing Treatments and Cures for Neurodegenerative Diseases, Testimony before the House Committee on

Energy and Commerce Subcommittee on Health, Editor. 2021, Food and Drug Administration,: Washington DC,.

9.   Shah, B.M., et al., Nose to brain microemulsion-based drug delivery system of rivastigmine: Formulation and ex-vivo characterization. Drug Deliv.,

2015. 22(7): p. 918-930.

10.   Yunusa, I., et al., Comparative value of cholinesterase inhibitors and memantine in persons with moderate-to-severe Alzheimer’s disease in the United

States: A cost-effectiveness analysis. J. Alzheimer's Dis. Rep., 2021. 5(1): p. 705-713.

11.   Peitzika, S.-C. and E. Pontiki, A review on recent approaches on molecular docking studies of novel compounds targeting acetylcholinesterase in

Alzheimer disease. Molecules, 2023. 28(3): p. 1084.

12.   Obaid, R.J., et al., Inhibitory potential of nitrogen, oxygen and sulfur containing heterocyclic scaffolds against acetylcholinesterase and

butyrylcholinesterase. RSC Adv., 2022. 12(31): p. 19764-19855.

13.   Kune, G.A., To-day's drugs: Methisazone. Br. Med. J., 1964. 2(5409): p. 621-621.

14.   Heffeter, P., et al., Anticancer thiosemicarbazones: Chemical properties, interaction with iron metabolism, and resistance development.

Antiox. Redox Signal., 2019. 30(8): p. 1062-1082.

15.   Zhang, Y., et al., Design, synthesis, and biological evaluation of novel substituted-thiourea derivatives as potential anticancer agents for

NSCLC by blocking K-Ras protein-effectors interactions. J. Enzyme Inhib. Med. Chem., 2020. 35(1): p. 344-353.

16.   Islam, M., et al., Synthesis and characterization of new thiosemicarbazones, as potent urease inhibitors: in vitro and in silico studies. Bioorg.

Chem., 2019. 87: p. 155-162.

17.   Hashmi, S., et al., Probing 4-(diethylamino)-salicylaldehyde-based thiosemicarbazones as multi-target directed ligands against

cholinesterases, carbonic anhydrases and α-glycosidase enzymes. Bioorg. Chem., 2021. 107: p. 104554.

18.   Jawaria, R., et al., Probing ferrocene-based thiosemicarbazones and their transition metal complexes as cholinesterase inhibitors. Inorg.

Chim. Acta, 2020. 508: p. 119658.

19.   Ishaq, M., et al., Synthesis, bioactivity and binding energy calculations of novel 3-ethoxysalicylaldehyde based thiosemicarbazone derivatives.

Bioorg. Chem., 2020. 100: p. 103924.

20.   Kuveke, R.E.H., et al., An international study evaluating elemental analysis. ACS Cent. Sci., 2022. 8(7): p. 855-863.

21.   Hameed, A., et al., Me3N-promoted synthesis of 2,3,4,4 a-tetrahydroxanthen-1-one: Preparation of thiosemicarbazone derivatives, their solid

state self-assembly and antimicrobial properties. New J. Chem., 2015. 39(12): p. 9351-9357.

22.   Tariq, S., et al., Synthesis, in vitro cholinesterase inhibition, molecular docking, DFT, and ADME studies of novel 1,3,4‐oxadiazole‐2‐thiol

derivatives. Chem. Biodiversity, 2022. 19(8): p. e202200157.

23.    Riaz, N., et al., New synthetic 1,2,4-triazole derivatives: Cholinesterase inhibition and molecular docking studies. Results Chem., 2020. 2: p. 100041.

24.   Perrella, F.W., EZ-FIT: A practical curve-fitting microcomputer program for the analysis of enzyme kinetic data on IBM-PC compatible computers.

Anal. Biochem., 1988. 174(2): p. 437-447.

25.   Nachon, F., et al., Crystal structures of human cholinesterases in complex with Huprine W and Tacrine: Elements of specificity for anti-alzheimer's

drugs targeting acetyl-and butyryl-cholinesterase. Biochem. J., 2013. 453(3): p. 393-399.

26.   Davis, I.W., et al., MolProbity: All-atom contacts and structure validation for proteins and nucleic acids. Nucleic Acids Res., 2007. 35(suppl_2): p.

W375-W383.

27.   Iman, K., et al., In silico structure-based identification of novel acetylcholinesterase inhibitors against Alzheimer's disease. CNS Neurol. Disord.: 

Drug Targets, 2018. 17(1): p. 54-68.

28.   Anwar, F., et al., New naphthalene derivative for cost-effective AChE inhibitors for Alzheimer’s treatment: In silico identification, in vitro and in vivo 

validation. Comput. Biol. Chem., 2020. 89: p. 107378.

29.   Roos, K., et al., OPLS3e: Extending force field coverage for drug-like small molecules. J. Chem. Theory Comput., 2019. 15(3): p. 1863-1874.

30.   Sastry, G.M., et al., Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichments. J. Comp. Aided Drug Des., 2013. 27(3): p. 221-234.

I would to love connect :), write to me at khan5g@uwindsor.ca